anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Marital satisfaction is a global evaluation of the state of one's marriage or current long-term romantic relationship. This global evaluation can be a reflection of a how happy people are in their marriage in general or a composite of satisfaction with several specific facets of the marital relationship. Sexual health can be described as enjoying and fulfilling sexual desires without harming, physical or psychological, oneself or others. Sexual functioning is an important part of a patient's health and well-being. Patients often seek for treatment late due to embarrassment and commonly with an alternative problem. Sexual and erectile functions are considered important components of men's overall health. The psychosocial impact of ED can lead to depression, loss of self-esteem, and relationship and marital difficulties. Personality is defined as the "distinctive and characteristic patterns of thought, emotion and behavior that define an individual's personal style and influence his or her interaction with the environment".
FIELD: medicine. SUBSTANCE: proposed agents contain mercuric chloride as active component together with natural grape wine or whey, it has 3-4 % content of sugar or honey. Proposed agents are used within definite ranges for internal administration, or as compress, as fomentation or as syringing separately or in various combinations. Additionally befungine is applied for external and internal administration. If patient have had a contact with heavy metals then internal administration of befungine takes place at the first step of treatment course. Proposed agents are used as internal and external means for treatment dermic disease and trophic ulcers. EFFECT: improves efficiency of treatment. 11 cl, 1 tbl
The invention provides a traditional Chinese medicine composition for treating acute, chronic and subacute leukemia and a preparation method thereof. 17 traditional Chinese medicines including radix rehmanniae, isatis, turtle shell, pawpaw, Barbary wolfberry, phellodendron bark, imported American ginseng, milk vetch, prepared fleece-flower root and the like are scientifically proportioned to synthesize oral capsules. The traditional Chinese medicine composition provided by the invention is sweet, acrid, slightly bitter, cold and astringent in property, does not have toxic side effects, has the functions of clearing away heat and toxic material, promoting appetite, inducing resuscitation and allaying a fever, strengthening the body resistance to eliminate pathogenic factors, inhibiting the growth of monocytes and leucocytes, normally reversing sick cells, conditioning the balance of a hemopoietic system, enhancing the immune function and hemopoietic function of the body, promoting the neogenesis of erythrocytes and hemoglobin and recovering the human health, and has a unique effect on treating acute, chronic and subacute leukemia. The dose for children is decreased with age or as specified by doctors. A patient with the disease needs to take the traditional Chinese medicine composition for more than six months until the hemopoietic system reaches the international normal value and then preferably takes the traditional Chinese medicine composition for another month for consolidating. Notes: patients can not eat acid, alkaline, choleric, pickled, sauced, acrid, spicy and high-protein foods when taking the traditional Chinese medicine composition, pregnant women need to take the traditional Chinese medicine composition carefully, and the traditional Chinese medicine composition can not be blended with Western synthetic hormone medicines.
AMA1-C1 + CPG 7909 is a blood stage malaria vaccine candidate. The primary objective of this Phase 1 study is to evaluate safety and reactogenicity of the vaccine in semi-immune adults in Mali. Secondary objectives are to evaluate the immunogenicity of the vaccine. The study is a double blind Phase 1 clinical trial in healthy adult volunteers. Volunteers will be screened and 24 participants will be enrolled and randomly assigned to one of the two groups: 12 volunteers will receive two doses of 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG; 12 volunteers will receive 80 microgram AMA1-C1/Alhydrogel, both at a 1-month dosing interval. Safety outcome measures are local and systemic (including laboratory) adverse events. Immune responses to vaccination will be measured by enzyme-linked immunosorbent assay (ELISA) and growth inhibition assay (GIA), and will be compared between groups. Peripheral blood lymphocytes will be assayed for the presence of AMA-1-specific memory B cells and for the total number of memory B cells.
The invention discloses hippocampal oxytocin AVT and IT and application thereof in preparing an oxytocic. The amino acid sequence of hippocampal oxytocin AVT is shown in SEQ ID NO. 2. The amino acid sequence of hippocampal oxytocin IT is shown in SEQ ID NO. 4. The invention separates hippocampal oxytocin AVT and IT with oxytocic effect from hippocampus, which can be used in delivery of hippocampus to regulate ITs oxytocic action.
Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
Abdominoplasty patients will be recruited. 50 patients will undergo classical closures.
A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy.
BACKGROUND: Cardiac troponin measurements are indispensable for the diagnosis of myocardial infarction and provide useful information for long-term risk prediction of cardiovascular disease. Accelerated diagnostic pathways prevent unnecessary hospital admission, but require reporting cardiac troponin concentrations at low concentrations that are sometimes below the limit of quantification. Whether analytical imprecision at these concentrations contributes to misclassification of patients is debated.
CONTENT: The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers (IFCC C-CB) provides evidence-based educational statements on analytical and clinical aspects of cardiac biomarkers. This mini-review discusses how the reporting of low concentrations of cardiac troponins impacts on whether or not assays are classified as high-sensitivity and how analytical performance at low concentrations influences the utility of troponins in accelerated diagnostic pathways. Practical suggestions are made for laboratories regarding analytical quality assessment of cardiac troponin results at low cutoffs, with a particular focus on accelerated diagnostic pathways. The review also discusses how future use of cardiac troponins for long-term prediction or management of cardiovascular disease may require improvements in analytical quality.
SUMMARY: Clinical guidelines recommend using cardiac troponin concentrations as low as the limit of detection of the assay to guide patient care. Laboratories, manufacturers, researchers, and external quality assessment providers should extend analytical performance monitoring of cardiac troponin assays to include the concentration ranges applicable in these pathways.
PURPOSE: To obtain a hair care composition capable of improving a flyaway problem such as fluffing of hairs and a difficulty in adjusting a hair combing, and transparent or not transparent by containing a quaternary silicone polymer. CONSTITUTION: This hair care composition contains at least one kind of a surfactant, a quaternary silicone polymer soluble to the surfactant but not soluble to water and having a terminal functional group and a cationic sedimented polymer as active ingredients. In the composition, 5-40wt.% surfactant, 0.01-1.0wt.% quaternary silicone polymer, 0.01-1wt.% cationic polymer are formulated. The quaternary silicon polymer has <=0.01wt.% solubility to water in 20 deg.C water and 50-120 unit length, and is expressed by the formula (R<1> , R<10> are each H, an alkyl, an alkenyl, etc.; R<2> to R<9> are each H, a lower alkyl, a lower alkenyl, etc.; X is an ion pair).
XELODA dosage may need to be individualized to optimize patient management. Patients should be carefully monitored for toxicity and doses of XELODA should be modified as necessary to accommodate individual patient tolerance to treatment (see CLINICAL STUDIES). Toxicity due to XELODA administration may be managed by symptomatic treatment, dose interruptions and adjustment of XELODA dose. Once the dose has been reduced it should not be increased at a later time.

The dose of phenytoin and the dose of coumarin-derivative anticoagulants may need to be reduced when either drug is administered concomitantly with XELODA (see PRECAUTIONS: Drug-Drug Interactions).

XELODA dose modification scheme as described below (see Table 18 and Table 19) is recommended for the management of adverse events. 

Dose modification for the use of XELODA as monotherapy is shown in Table 19.

Dosage modifications are not recommended for grade 1 events. Therapy with XELODA should be interrupted upon the occurrence of a grade 2 or 3 adverse experience. Once the adverse event has resolved or decreased in intensity to grade 1, then XELODA therapy may be restarted at full dose or as adjusted according to Table 18 and Table 19. If a grade 4 experience occurs, therapy should be discontinued or interrupted until resolved or decreased to grade 1, and therapy should be restarted at 50% of the original dose. Doses of XELODA omitted for toxicity are not replaced or restored; instead the patient should resume the planned treatment cycles.
Colorectal cancer (CRC) is the third most common cancer worldwide, the second deadliest cancer in the United States. DNA methylation is a commonly used biomarker for non-invasive CRC detection in plasma. The low sensitivity of blood-based tests is due to several limitations of detecting ctDNA in early-stage cancer. We developed and validated a high-throughput methylation-based blood test highly sensitive for colorectal cancer and precancerous lesions. This previously established colorectal tumor-specific plasma ctDNA methylation markers (diagnostic model established by next-generation sequencing of 2181 gene loci methylation) had a high sensitivity in CRC patients and a high specificity in healthy individuals in a large retrospective sample study. This prospective, clinical study is to further evaluate the sensitivity of plasma ctDNA methylation haplotypes in detecting local residual or lymph node metastasis.
The literature presents a number of studies on the reconstruction of the anterior cruciate ligament, as well as numerous registers, but the identification of factors and parameters determining the clinical outcomes remains largely debated. The study aims to offer new elements to analyze this treatment and potentially identify the factors responsible for the outcomes and the factors useful to optimize the clinical outcome in the future. In fact, in addition to collect patient data in terms of features and clinical-functional status, objective data will be documented and correlated. In particular the quantification of knee laxity will be performed using an innovative device based on the use of inertial sensors (a methodology recently developed and already validated at the Istituto Ortopedico Rizzoli). The study is intended to include all patients who will undergo surgical reconstruction of the anterior cruciate ligament (ACL). These patients will be followed and evaluated preoperatively, at 6 months and at 1, 2 and 5 years after surgery during a clinical visit or a telephone interview. Such evaluations will include the submission of questionnaires to determine the patient's functional symptoms and also knee joint assessment during a medical examination to quantify the knee joint stability.

Moreover, the following clinical scores will be adopted: IKDC-subjective, IKDC-objective, SF12, Marxs, Koos, Tegner, VAS for pain assessment, EQ-VAS for overall health status assessment. Also it will be recorded the lapse of time for returning to work and sports, the degree of patient satisfaction,the adverse events, the failures and any new treatments on the same site.
Cancer-related fatigue (CRF) is a distressing side effect of cancer and treatment, affecting both patients during active treatment and survivors, negatively impacting quality of life. While its exact cause remains uncertain, various mechanisms such as immune dysfunction, HPA-axis dysfunction, and treatment toxicity are proposed. Inflammatory biomarkers of CRF have been explored in previous research, but non-inflammatory markers have not been comprehensively studied. This systematic review analysed 33 studies to identify non-inflammatory peripheral blood biomarkers associated with CRF. Promising markers included Hb, blood coagulation factors, BDNF, tryptophan, GAA, mtDNA, platinum, CA125, and cystatin-C. Inconsistent findings were observed for other markers like VEGF, leptin, and stress hormones. Most studies focused on adults. Research in pediatrics is limited. This review showed partial evidence for the inflammaging hypothesis (neurotoxicity due to neuro-inflammation) laying at the basis of CRF. Further research, especially in pediatrics, is needed to confirm this hypothesis and guide future biomarker studies.
Long-acting beta2-agonists and anticholinergics are main drugs in therapy of chronic obstructive pulmonary disease . Beta-agonists exert their bronchodilatory effects via β2 adrenoceptors located on airway smooth muscle cells. Anticholinergics block mainly M3-cholinoreceptors located in the airways, thus inhibiting bronchoconstriction. Metacholine blocks M2-cholinoreceptors thus inducing bronchoconstriction. It is known, that muscarine and beta-receptors interact with each other, but the detailed mechanism is unknown. For evaluating the binding activity of beta-receptors after inhalation of these drugs the modified radioligand method was used.
FIELD: medicine, reanimatology. SUBSTANCE: method includes laser irradiation of taken blood in transparent tube of perfusion line until hemosorption and return of blood to portal vein. Laser irradiation is carried out after application of working end of laser radiator light guide to tube of perfusion line up to sorption column and enveloping it and tube with laser5 reflecting screen. The latter is made of foil flexible sheet. EFFECT: accelerated supply of optimal volume of oxygen to liver lesion focus and reduced toxicity of supplied blood. 2 cl, 1 ex
Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Subjects randomized to the Intervention arm will receive standard of care plus 1.2 grams of tobramycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
FIELD: data control systems. ^ SUBSTANCE: portable devices have first device for making first operation and second device for making second operation. Any device has aid for making one or several following operations: storage, transmission, processing and representation of data. Two devices have set of mutually related positions during common usage. Method has the following steps: automatic saving of at least first data relating to mentioned first operation in mentioned first device; automating saving of at least two data being relevant to mentioned second operation in mentioned second device; automatic transmission of data being relevant to at least one of mentioned first and second operations between first and second devices in case when mentioned devices are mutually positioned in one mutually related positions in set. Automatic transmission is performed through close action device. ^ EFFECT: simplified and comfortable self-therapy. ^ 37 cl, 7 dwg
Cobalamins are recovered from solutions thereof in water-insoluble phenols by adding an organic base to the phenolic solution capable of forming a water-insoluble complex with the phenol whereby the solubility of the cobalamins in the phenol is reduced due to such complex formation.  Water may be added to the phenolic solution to extract the cobalamins.  The phenolic solution of cobalamins may be obtained from an aqueous solution thereof by treatment with a water-insoluble phenol.  The starting materials may be obtained from liver and other naturally-occurring products or from the fermentation liquors of micro-organisms.  As phenols there may be used alkyl phenols, e.g. cresol, xylenol, amyl phenol and normal octyl phenol; the halo phenols, e.g. p-chloro phenol; p-nitro phenol; the acyl phenols, e.g. p-hydroxy acetophenone and p-hydroxy benzaldehyde; phenolic carboxylic acid esters, e.g. p-hydroxybenzoic acid ethyl ester and phenolic ethers, e.g. hydroquinone monomethyl ether and solid phenols in an inert solvent.  As organic bases there may be used pyridine 2-4-lutidine triethyl amine, 2-ethylhexylamine, mono-butylamine, ethyl-morpholine, dimethylaniline and commercial mixed collidines. The examples also describe the use of 2-methyl-5-ethyl pyridine and aniline.  Specification 469,430, [Group VI], is referred to.
Municipal or septic tank sewage water is clarified and subjected to combined treatment, such that the aerobic and anaerobic treatment spaces are separated by suitable elements. - Sewage removed from septic tanks by a tanker lorry is discharged by the tanker's own equipment and simultaneously strained. The water phase is distributed into the lower (anaerobic) section of the treatment plant. The rising effluent water, rich in colloids, is clarified by contact with the suspended sludge. The water continues to rise into the aerobic space where it is further purified and/or strained. The gases generated are collected and piped away, and in some cases the water is further treated. - The proposed equipment is divided into anaerobic and aerobic treatment spaces by suitable guide elements. Effluent water is routed from a feed tank arranged with a solids trap. Water is supplied to the anaerobic treatment space by a feed pipe. Reversed `L' shaped elements divide the anaerobic reactor space and the aerobic settling space. The tops of the separator elements are connected to a gas collector header and gas discharge pipe. The lower pts of the separator elements are provided with covered slots. (Dwg.0/1)
Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). MMR expression and MSS status are the important effective factors of immunotherapy. PD-1monocolnal antibody therapy has accessed excellent treatment effect in advanced dMMR/MSI-H CRC and neoadjuvant therapeutic effect in early colon cancer, more than fifty percent of dMMR/MSI-H CRC patients might get pathological complete response(pCR) after PD-1 monoclonal antibody treatment. The treatments had been proved to be safe and the toxicities were controllable. However, for proficient mismatch repair(pMMR)/microsatellite stable(MSS) CRC, the curative effect of PD-1 monoclonal antibody was poor and most of the data came from stage Ⅳ patients with distant metastasis. Among the whole CRC patients, more than eighty-five percent were pMMR/MSS CRC. It would be very inspiring when major CRC patients(pMMR/MSS) could be benefit from immunotherapy. For T4NxM0 CRC patients, R0 resection was difficult to achieve. If the patients could not got R0 resection, which means the tumors were almost destined to recurrent and patients life time were counting down. However, there were no standard conversion of neoadjuvant treatment recommendations for T4NxM0 CRC. Although PD-1 monoclonal antibody alone has poor effect in pMMR/MSS CRC, it seems to be effective in early stage of MSS CRC(Nicole study) or when it was combined with chemotherapy or target therapy. So far, whether combined treatment of mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody could maximize the curative effect was still unknown. This study aims to evaluate the effect and safety of mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced(T4NxM0) pMMR/MSS CRC.
The present invention addresses the problem of providing: a 3-substituted uracil compound that has excellent germicidal/antimicrobial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/horticultural germicide containing the compound as an active ingredient. Further, the present invention addresses the problem of providing a nematicide containing the aforesaid compound as an active ingredient. Furthermore, the present invention addresses the problem of providing a medical and animal antifungal agent containing the aforesaid compound as an active ingredient.　Provided is a compound represented by formula (I) or a salt thereof.　In formula (1): Y represents an oxygen atom, etc.; X 1  and X 2  each independently represent a hydrogen atom, a halogeno group, a substituted or unsubstituted C1-6 alkyl group, etc.; X 3  represents a group represented by R N1 -CO-NR N2 -, etc.; R N1  and R N2  each independently represent a hydrogen atom, a substituted or unsubstituted linear C1-6 alkyl group, etc.; A represents a substituted or unsubstituted C1-6 alkylene group, etc.; and Q represents a substituted or unsubstituted C6-10 aryl group, etc.
Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.
There are currently two options: 1) Simvastatin （Simvastatin Tablets）80 mg QD orally for up to 28 days in patients with acute lung injury. 2) Rosuvastatin （Rosuvastatin Calcium Tablets）40 mg for the first time, followed by 20 mg orally daily for 28 days, or 3 days after being transferred out of the ICU, or after the patient died.